What did Needham do to IONS on Feb 25, 2026?

Needham maintained a **Buy** rating and raised the **price target to $103 from $90** on Feb 25, 2026, according to TheFly. The firm kept its positive view while marking higher valuation upside.

What was RBC Capital’s action on IONS on Feb 25, 2026?

RBC Capital reiterated an **Outperform** rating on Feb 25, 2026. RBC maintained its prior stance without a reported price target change, signaling steady analyst confidence.

How do maintained ratings affect investors’ decisions?

Maintained ratings suggest analysts see no new negative evidence. Investors should weigh maintained positive ratings with company catalysts like FDA reviews and earnings before changing positions.

What is Meyka’s view of IONS right now?

Meyka AI rates IONS with a grade of **B**, factoring in benchmarks, sector performance, growth, metrics, and analyst consensus. This grade is informational and not investment advice.

Analyst Ratings

Needham Maintains Buy on Ionis Pharmaceuticals (IONS) Feb 25, 2026

ByHuzaifa Zahoor February 26, 2026February 26, 2026

On February 25, 2026 Needham maintained a Buy on Ionis Pharmaceuticals, Inc. (IONS) and raised its price target to $103 from $90. This action is part of two analyst moves the same day, as RBC Capital reiterated an Outperform on IONS. The IONS analyst rating update signals continued analyst confidence while the shares showed small intraday dips. We use Meyka AI real-time coverage to track these moves and what they mean for investors.